Develops therapies for ocular and inflammatory diseases, focusing on novel drug targets and treatments.
OKYO Pharma Limited, headquartered in London, United Kingdom, is a pioneering preclinical biopharmaceutical company dedicated to advancing therapies for inflammatory eye diseases and ocular pain. Established in 2007, the company specializes in developing innovative treatments aimed at improving the quality of life for patients suffering from these debilitating conditions. Central to OKYO Pharma's pipeline is OK-101, its lead product designed specifically for addressing dry eye disease, a prevalent and challenging condition affecting millions worldwide.
In addition to OK-101, OKYO Pharma is actively developing OK-201, a promising candidate derived from bovine adrenal medulla, which features a lipidated-peptide preclinical analogue. This novel therapy targets neuropathic ocular pain, an area of significant unmet medical need. By leveraging cutting-edge research and development strategies, OKYO Pharma aims to deliver impactful solutions that alleviate symptoms and enhance outcomes for patients experiencing ocular discomfort and inflammation.
Through its innovative approach and commitment to scientific rigor, OKYO Pharma Limited continues to expand its portfolio of therapeutic candidates while advancing the forefront of ocular health research. The company's efforts underscore its dedication to addressing the complex challenges associated with inflammatory eye diseases and ocular pain, positioning itself as a key player in the biopharmaceutical landscape.